New Approval Marks a Milestone for Medical Imaging
Technology
SYDNEY — Claritas NucMed Technologies Ltd has received approval from the Australian Therapeutic Goods Administration (TGA) to supply its Claritas iPET software for medical use in Australia. This decision, announced on March 6, 2026, allows the software to be integrated into hospital systems across the country to enhance the quality of PET scans.
The Claritas iPET software, which is device-agnostic, improves the clarity and visibility of PET scans, even those conducted with reduced time or dosage, according to a statement from Claritas. The company highlighted that this technology aids in maintaining diagnostic quality while increasing the efficiency of imaging procedures.
Dr. Fernando Salis, Director of Claritas NucMed Brazil, noted, “We are extremely pleased to see the response and demand in Brazil, where hospitals have implemented Claritas iPET to improve the quality and efficiency of PET scans.” This approval follows successful uses in other jurisdictions, reflecting a growing trend in the sector for enhanced imaging technologies.
Impact on Medical Imaging in Australia
The approval of Claritas iPET in Australia comes amid increasing demand for advanced imaging solutions in the healthcare sector. The software enables hospitals and clinics to overlay CT or MRI data with PET scans for better diagnostic information. According to Claritas, this development is expected to improve patient throughput and reduce costs by minimizing scan times and radiation exposure.
Claritas HealthTech Ltd, the parent company based in London, specialises in image enhancement and AI technologies aimed at transforming diagnostic procedures. The company confirms that all its products meet international privacy and data protection standards.
Source: newshub.medianet.com.au
Last updated: 4 April 2026, 8:24 pm
